Targeting the IDO1 pathway in cancer: from bench to bedside

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Indoleamine 2,3-dioxygenases (IDO1 and IDO2) and tryptophan 2,3-dioxygenase (TDO) are key enzymes in tryptophan metabolism.
• These enzymes convert tryptophan to kynurenine, influencing the tumor microenvironment.
• IDO1 plays a critical role in tumor progression and immune evasion.

Purpose of the Study:

• To review the function of the IDO1 pathway in tumor progression and immune surveillance.
• To highlight therapeutic strategies targeting IDO1 in cancer immunotherapy.

Main Methods:

• Literature review of preclinical and clinical studies on IDO1 pathway in cancer.
• Analysis of IDO1's role in immune suppression and tumor growth.

Main Results:

• IDO1 activation leads to tryptophan depletion and kynurenine accumulation, promoting immunosuppression.
• IDO1 pathway supports tumor growth by activating regulatory T cells and myeloid-derived suppressor cells.
• IDO1 inhibition demonstrates therapeutic potential in various cancer models.

Conclusions:

• Targeting the IDO1 pathway is a promising strategy for cancer immunotherapy.
• IDO1 inhibitors, peptide vaccines, and other approaches are under investigation.
• IDO1 inhibition offers a therapeutic avenue beyond checkpoint inhibitors and CAR T-cell therapy.